newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - DYNE THERAPEUTICS INC

Okay, we're going to get started with the next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. And it's my pleasure to have the Dine team with me. To my direct right is John Cox, CEO, and to his right is Eric Lucera, CFO. Welcome, both of you. Thank you. So maybe give us an introduction about Dine, first and foremost, what your differentiation what you're trying to achieve milestones over the next three to 12 months could also be helpful yeah thank you thanks for having us Andrew um well 2026 has been one incredible year for this company a transforming year for the company in terms of clinical progress regulatory progress I and essentially building the kind of scale and infrastructure we need to transform certain markets next year DMD being the first that we expect to launch our first product in you know kind of getting back to what we're trying to do and accomplish as a company this company was it was founded on the notion that in neuromuscular genetic disorders the aliquot nucleotide or nucleic acid sequences are known but maybe one of the biggest biotech hurdles or challenges has been how to deliver those nucleic acids in sufficient quantity, broadly and deeply enough to tissue. And this company developed a platform that we call the FORCE platform to do that. And I think our scientists have overcome what is one of the biggest biotech challenges. And we demonstrated that at the end of last year in two very difficult diseases, DMD and myotonic dystrophy type 1. In both of those diseases, we showed clinically in humans using the same delivery platform that we were able to generate functional improvement across multiple efficacy measures. Not slowing of decline, but actual improvement from baseline. That's never been seen before. It's a remarkable accomplishment. And so we went into this year thinking deeply about our capital allocation strategy for our shareholders. And it's good to have Eric here, and he can talk about that some more. But that strategy was to make sure we're investing in regulatory and regulatory execution, clinical and clinical execution across multiple trials and late-stage trials, and to build out our commercial organization to prepare ourselves to be able to launch these products ourselves in the United States. That's going to be happening, we believe, beginning next year in Q1. And we also have some very important data in DM1 that I'm sure you're going to want to talk about that we expect to turn over, registrational endpoint data that we suspect to turn over in Q1 of this year as well, this coming year. Perfect. And so maybe this time around I would love to ask on DM1 first for the Q1 readout. And so to start off, the elephant in the room is Novartis did fail recently on their own phase three and so on one you know what's interesting is novartis still sees a path forward on one hand i think you guys could be the first mover on the other hand the primary end point for your own pivotal study for accelerator approval is also v hot so can you uh reassure investors uh why you guys will show stat sig on v hot yeah i'm happy to i first of all i think everybody was disappointed in Novartis result and it was it was unfortunate for the field and for the patients and we were surprised because the endpoint that you're referring to video hand opening time which is a reflection of my atonia I is an endpoint that moves very easily and I think everybody expected that to be easy to hit as long as you had a dose that was generating sufficient splicing correction. And I just remind people that the core kind of pathobiology of this disease is it is a splicing or mis-splicing issue occurring in the nucleus of the cell throughout most of the cells of the body. And so you have to have a dose that's engaging in the nucleus. And i say that because our product which gets to your question why we still believe is that our product uses a very different payload than the Novartis drug. We use an anti-sense oligonucleotide. We use that intentionally because it's designed to get to the nucleus where the core issue is. And we have demonstrated very clearly splicing correction throughout our dose escalation and at our highest dose. And sufficient splicing correction, not only to correct or prove on VHOT and hemimiotonia, but on a variety of more even more important functional measures and i'll just add that for us v hot is an endpoint that we're using as an intermediate clinical endpoint not as a phase three endpoint it's being used as an intermediary clinical endpoint for accelerated approval it's an early indicator frankly it's not that clinically meaningful uh but it is an early indicator of other functional benefit of which we need to show trends for accelerated approval so we we've looked at the stats we have 71 patients in this uh this registration expansion cohort and we believe we will be stat sig on v hot we think we'll be statistically significant on splicing correction and we also believe that we should see trends and multiple functional measures that really matter to this community got it thank you and um i suspect it's i don't know the answer novartis for them to move forward and mentioning you know they it sounds like they saw hints of efficacy and other endpoints outside of v hot i suspect that the placebo for v hot was a bit noisy i don'T know again i DON'T know um but it begs the question um you know did you guys factor in a placebo response and in terms of trial execution, how have you tried to curb for a placebo response? You know, I don't, I think like you, I'm just hearing about what may have happened. It's all speculation. Hopefully there'll be some data presented at an upcoming conference. I think they've indicated they'd do that. I'll just tell you how we've handled it from a VHOT standpoint. First of all, we saw VHOT improve at our lowest dose of 1.8 mg per kg. Not the dose we're using for registration, but 1. 8 mg per kg. We went all the way up to 6.8 mg per kg, so we know we're well above where we need to be for pharmacological activity. In terms of our placebo studies, as we've done that work with our multi-accenting dose, I think we had 14 placebo patients. We saw there is, of course, variability from patient to patient. The key is that you don't have variability within the patient or for that given patient. But what we saw with the placebo is that we saw a slight worsening of placebo of 0.4 seconds. That's pretty consistent with natural history, and there's plenty of papers. I think there's a paper out recently by Lewenberg really on VHOT talking about the stability of VHAT over time for a given patient. So I think the idea of random placebo issues is really a matter of conducting the test in a rigorous way, and we've been doing that. We have put a tremendous amount of effort through our studies on how we do the testing, the training by master physical therapists and how the test should be done for each site. We have the same physical therapist with that patient through the testing periods, so you don't have kind of tester variability, and I could go on. And we take duplicates. So the key here is to make sure that you are getting an accurate, truthful baseline number when you do it. And I think we've taken the right steps to make Sure that happens. And speaking of the baseline, you recently shared the baseline scores of VHOT for your pivotal cohort that reads out in Q1. So what's the take-home message there? and do the values there make you more confident that this upcoming study will succeed? Well, I think they do. I'll tell you the intent of that work. Listen, we had anticipated that at World Muscle that Novartis would be presenting data for 12-month data. they would pass on VHOT and that we would get to see what they were getting on some of the other functional measures in 12 months. What we were trying to do most recently was put together a cohort of 25 patients and present that data in terms of the functional measures at 12 months so you could compare. But we also provided six-month VHAT data. We also provided, as you said, the baseline mean data for VHOT for the Registrational Expansion Court of 71 patients. And if you start comparing those baseline kind of means, they're comparable across the MAD, across that summed up group of cohorts that we had of 25 patients, and with the 71 patients, And I think what that does is tell you that what we ought to see in the 71 with the REC will be similar to what we've seen previously with the MAD. And that's what our stats have all been based on. So we're comforted by seeing kind of the baseline, the baseline standard deviation, and how it kind of compares to natural history, et cetera. And it also speaks, I think, a lot to how disciplined we have been about inclusion and exclusion criteria and the rigor of which we've conducted every aspect of this clinical development program. Very good. And so as we think about the accelerated approval pathway, VHOT obviously needs to hit STAT-SIG as your primary endpoint. You mentioned you're confident in splicing hitting STAT‑SIG. Is that necessary for accelerated approval, or is it more about the outcome measures you're measuring? It's not necessary. It's certainly helpful because I believe the FDA understands full well the importance of splicing and its implications for effect on the disease. But to be clear on accelerated approval, that type of pathway, you are expected to have statistical significance on either an intermediate clinical endpoint or a molecular biomarker. We should have statistical significance on VHOT as the intermediate clinical endpoint. We should statistical significance on the molecular biomarker splicing correction. And then the other expectation is that in addition to hitting on the VHAT that you would see trends, a reason to believe that that early indicator will have functional effect over time. Those trends do not have to be stat-sig, but you've seen, Andrew, you've seen our trends, and you don't have to squint to see that those trends are showing improvement relative to baseline and or placebo across multiple, multiple functional measures. Got it. And just to clarify, you're evaluating maybe four or five outcome measures. As long as one out of five at least shows a trend, you are good. Well, with accelerated approval, it's in the eyes of the FDA. Understood, yeah. And you've seen accelerated approvals happen with one trend, sometimes very low correlations for diseases that are rare and difficult and for which a drug is needed. we've seen those types of trends across quantitative muscle testing time function tests like 10 meter walk run five times sit to stand we've even seen it on patient reported outcomes and even at the highest dose in the registrational dose we saw those trends very clear trends on cns effect on the cns subscales of md high i'd be surprised if there's just one I understand. Yeah. Okay. And so, hypothetically speaking, if this cohort, or sorry, this pivotal cohort did not succeed on VHOT, you technically have two shots on gold because, like you said, you're running the phase three confirmatory study. Is that the right way to think about it? And if so, when could the confirmatory data be? I'll let Rick run with this. Yeah, so as you mentioned, we are running a phase three confirmatory trial called Harmonia, which has 150 patients randomized one-to-one. We have not given timelines yet for when that will be completed, but a good analog would be Avidity, where they had a similar trial, 150 patients one-To-one, took about 16 months to enroll. The endpoint for our trial is five-time sit-to stand, and we have done a tremendous amount of work with KOLs, and we believe that is absolutely the best primary endpoint to have for these patients because it really does show the effect of the drug in terms of giving people quality of life. It measures the whole body, and standing up from a chair is not the easiest thing to do. It's a very rigorous test, and we think it's an endpoint that as clinicians and even investors start to do the work on it, they're going to come to see that we made the right choice. Yes. If it took 16 months to enroll and then another year for data, is that how I can think about it as an analog? That's a good analog. Okay. It's the only one out there. Yes, yes. And then back to this pivotal readout, how should we think about the safety profile? Any SAEs, drug-related SAEs we should be thinking about? You know, we had our last safety update not too long ago, and there have been no serious TEAs and if that changes I mean we monitor obviously in a blinded way and if that changes in some material way we'd let you know but the safety profile has been I think in our opinion quite favorable. Okay very good so good luck on that data readout seems like you've executed well fingers crossed and then shifting gears to DMDX on 51 where the PDUFA is January which I feel like could be before DM1, you don't need to say if so. But you're launching in Q1, it sounds like. And so, how have the FDA discussions been going so far? Well, it's 66 days. We have a countdown clock in our main building. So, it is 66 days We just, as a matter of policy, have not been providing play-by-play regulatory. So we are not going to do it. We are just too close to our PDUFA date, so it won't be coming. Okay. And then as I think about the label, to the extent you are willing to share, what could be included in the Section 14 of the label? Is it just dystrophin? Because you did see these nice outcome measures. Could that also be included? With accelerated approval, that is also up to the FDA. Normally you want to get as much in the label as you can, and I'd love to do that, but I will tell you for a rare disease like this in DMD, the doctors know the data, the families know the date, everybody is familiar with it. If you look at the current, if you want to call it, I guess the standard of care would be E. Teplerson today. They have a broad label in terms of age and so on. I would expect at a minimum we'd have our dystrophin data in there, but the more data, The more that we have in there on function, that's great, but I don't think that's a prerequisite for us to have a successful launch. Makes sense. And in terms of price, you've frequently mentioned Exondys being a million dollar price point. Is that the floor on price? Well, obviously it's a little too early to comment specifically on pricing, but I think the Exondy example is a good one for folks to use in their models. As a reminder, we are bringing patients lot of value for this drug. The current therapy is administered weekly, and we're monthly. They don't have a lot of function, if any, data out there in their label. We've got six functional endpoints, you know, to drive value for these patients, in addition to a significant increase in dystrophin relative to standard of care. So we think we're bringing a great value to the community, and, and will announce pricing when we're, when we got it locked down. Sounds good. And let's just say you are approved in January. How many weeks does it take for you to actually launch? We're saying it will be in Q1. You know, typically there is a short period of time. There's a short time period. There's going to be a short amount of time after you get approval that, you know, just getting supply through and out to patients takes a little bit of time, but that will be normal. Okay. Okay, and do you plan to provide free drug at all, or is this? Right now, the inventory plans and strategies are to make sure that we keep all the clinical patients on drug, that we are supplying for the phase three, and also that we're building inventory and ready for a successful commercial launch. So that's really the focus right now. Okay, and in terms of the market opportunity, Exondys, we've discussed this before, I believe 500 patients in the US, but there's also a pool of naive patients, 500, and then discontinuations, 500 patients too. So 1,500 total, where is the low-hanging fruit in your group in the first year? I think, you know, our intention is to get this drug to every boy that we can. You know, we don't see it as sort of low- hanging fruit. This is a therapy that these boys need, and it's our moral duty to make sure that we get as many of these kids on this as fast as possible. Yes. I think the way it breaks out is we've been estimating about 1,600. We've been building out a commercial organization. The last two years have been building a leadership team, and the last kind of nine months to a year has been, under Johanna Friedl-Nader, are building out, I think, a world-class rare disease neuromuscular expert group of people. That includes people that are working with payers already, focused on market access and understanding the market. So we think there's about 1,600 patients out there, maybe 500 or so on the current treatment of eteplosin. There's probably another 500 that had tried eteplecin and dropped off of it. So, I would think those groups in particular would be particularly attentive to this launch. I see. And that's just U.S. Right. And then, oh, you had a question? Oh, you had a question? John, in the event that you're approved, how can you take that approval and kind of make it a flywheel as opposed to each specific mutation kind of becomes its own set of toxicology, own experience? Yeah, I'm glad you raised it, Chris. And for those that may not have heard the question, when we talk about the patients today and what we just quoted, the 1,600 is about 13% of that entire DMD population in the United States. We have already taken our platform, and Ram Batra, who is our CSO, has already created the drug candidates, and we're moving them through our pre-IND process. Because they're so de-risked, I mean, exon 51 is arguably the toughest exon to skip. So we have the exon skipping data in our models. We're moving those forward. And I'll tell you, our ambition here is to become leaders in DMD, and it is to go beyond exon51 and build from that. flywheel as you describe it the next step with that is once we have this first drug approved with the FDA is to sit down with the FTA and they have so many wonderful initiatives that you've been hearing about certainly the ambition of the FDA now to be able to get these types of drugs to patients in a streamlined way I think we we should be front and center of that effort and we intend to be okay and then maybe a couple more questions on the commercial side. How many sales reps do you need? What do COGs look like? Yeah, this is a prototypical rare disease market. You know, we haven't disclosed the specific number of reps yet, but if you think about it, there's about 100 centers in the U.S. where 80% of the boys are. So it's a pretty dense group. So we feel like we can have a very capital-efficient commercial model that we will used not only for DMD, but the same organization that will scale a little bit for DM1 and then add the other four exons to it, plus FSHD. So we have the opportunity to have seven different products all running through the same commercial organization. In addition to the second part of your question with respect to cost of goods, those same drugs will also be running through this same CMC process, same FAB, same linker, et cetera, et cetera. We expect in the beginning a lot of the COGS will be inventory that's already been expensed for R&D, but as we scale it, we do expect to get to ADC-like gross margins over time. So we think the combination of having seven products all through the same commercial and manufacturing infrastructure should allow us to, as we get into the next decade, have above-average growth rates, above-average profitability margins, and a really great specialty pharma story. Great. And then ex-U.S. opportunity, because I feel like Exondus has made a good traction there, too, but I'd imagine you want to go ex-US yourself. So what's the strategy there? So, you know, I mentioned that we have these confirmatory phase threes. They're confirmatory from the standpoint of supporting accelerated approval in the United States, but they're phase threes from a global perspective. there is some exondus in places like the Middle East but Europe does not have drugs available for DMD that market is the size of the US market they desperately need these types of therapies and we're conducting a phase 3 that we think will definitively allow us to get approval there and Japan is the same story so we wholly own the assets. We haven't partnered them. It is an opportunity for us to be able to go global in a sequential way and through the same infrastructure for both drugs commercially and CMC, as Eric was saying. And then let me, last question, timelines for the remaining earlier stage programs. We've discussed the other exons. There's FSHG, Pompe. When do those enter the clinic. So the other exons are clearly a priority. FSHD is also a real priority for us. I think our platform is ideally suited for addressing that disease because of the depth and breadth that we get to the tissue, and that's going to be needed. So FSHT, we have an IND approved, and we are moving forward towards the clinic right now. So hopefully we can talk more about that in the coming year okay I think that's all the time we have thank you so much for the updates thank you so luck and thank you everyone

Company
DYNE THERAPEUTICS INC
Keywords
DYNE THERAPEUTICS INC